Alec has more than 30 years of experience in pharmaceutical drug development principally in respiratory, allergy and gastrointestinal medicine. Alec has been CEO of Lamellar since November 2011. Prior to this he was Global Head of Respiratory and Allergy product development at Quintiles, where he was employed for 14 years. His main areas of responsibility were full service clinical product and program execution, product development strategy and product and company due diligence for the commercial wing of Quintiles. His typical portfolio exceeded $300m, with yearly sales of around $100m. Alec delivered pivotal studies for a range of pharma companies including Roche, AZ, Merck, Novartis, J&J and Vertex. Alec moved to Quintiles from AstraZenca where he held the position of Head of Projects. Prior to working in industry Alec was a Research Fellow at Edinburgh University Medical School working on the pathophysiology of COPD having completed his PhD on this subject.